» Articles » PMID: 30411243

Mean Arterial Pressure and Mortality in Patients with Distributive Shock: a Retrospective Analysis of the MIMIC-III Database

Overview
Specialty Critical Care
Date 2018 Nov 10
PMID 30411243
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Maintenance of mean arterial pressure (MAP) at levels sufficient to avoid tissue hypoperfusion is a key tenet in the management of distributive shock. We hypothesized that patients with distributive shock sometimes have a MAP below that typically recommended and that such hypotension is associated with increased mortality.

Methods: In this retrospective analysis of the Medical Information Mart for Intensive Care (MIMIC-III) database from Beth Israel Deaconess Medical Center, Boston, USA, we included all intensive care unit (ICU) admissions between 2001 and 2012 with distributive shock, defined as continuous vasopressor support for ≥ 6 h and no evidence of low cardiac output shock. Hypotension was evaluated using five MAP thresholds: 80, 75, 65, 60 and 55 mmHg. We evaluated the longest continuous episode below each threshold during vasopressor therapy. The primary outcome was ICU mortality.

Results: Of 5347 patients with distributive shock, 95.7%, 91.0%, 62.0%, 36.0% and 17.2%, respectively, had MAP < 80, < 75, < 65, < 60 and < 55 mmHg for more than two consecutive hours. On average, ICU mortality increased by 1.3, 1.8, 5.1, 7.9 and 14.4 percentage points for each additional 2 h with MAP < 80, < 75, < 65, < 60 and < 55 mmHg, respectively. Multivariable logistic modeling showed that, compared to patients in whom MAP was never < 65 mmHg, ICU mortality increased as duration of hypotension < 65 mmHg increased [for > 0 to < 2 h, odds ratio (OR) 1.76, p = 0.005; ≥ 6 to < 8 h, OR 2.90, p < 0.0001; ≥ 20 h, OR 7.10, p < 0.0001]. When hypotension was defined as MAP < 60 or < 55 mmHg, the associations between duration and mortality were generally stronger than when hypotension was defined as MAP < 65 mmHg. There was no association between hypotension and mortality when hypotension was defined as MAP < 80 mmHg.

Conclusions: Within the limitations due to the nature of the study, most patients with distributive shock experienced at least one episode with MAP < 65 mmHg lasting > 2 h. Episodes of prolonged hypotension were associated with higher mortality.

Citing Articles

Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart for Intensive Care-IV Database.

Haddad G, Maslove D, Mbuagbaw L, Belley-Cote E, Rochwerg B Crit Care Explor. 2025; 7(2):e1210.

PMID: 39888591 PMC: 11789865. DOI: 10.1097/CCE.0000000000001210.


Deep learning model to identify and validate hypotension endotypes in surgical and critically ill patients.

Jian Z, Liu X, Kouz K, Settels J, Davies S, Scheeren T Br J Anaesth. 2025; 134(2):308-316.

PMID: 39788817 PMC: 11775843. DOI: 10.1016/j.bja.2024.10.048.


Mean arterial pressure at the initiation of continuous renal replacement therapy as a prognostic indicator in patients with acute kidney injury.

Song H, Liao Y, Hu H, Wan Q Ren Fail. 2025; 47(1):2448582.

PMID: 39763014 PMC: 11721759. DOI: 10.1080/0886022X.2024.2448582.


Oral blood pressure augmenting agents for intravenous vasopressor weaning.

Robinson J, ElSaban M, Smischney N, Wieruszewski P World J Clin Cases. 2024; 12(36):6892-6904.

PMID: 39726934 PMC: 11531983. DOI: 10.12998/wjcc.v12.i36.6892.


Early management of adult sepsis and septic shock: Korean clinical practice guidelines.

Park C, Ku N, Park D, Park J, Ha T, Kim D Acute Crit Care. 2024; 39(4):445-472.

PMID: 39622601 PMC: 11617831. DOI: 10.4266/acc.2024.00920.


References
1.
Asfar P, Meziani F, Hamel J, Grelon F, Megarbane B, Anguel N . High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014; 370(17):1583-93. DOI: 10.1056/NEJMoa1312173. View

2.
Brown S, Lanspa M, Jones J, Kuttler K, Li Y, Carlson R . Survival after shock requiring high-dose vasopressor therapy. Chest. 2012; 143(3):664-671. PMC: 3590882. DOI: 10.1378/chest.12-1106. View

3.
Leedahl D, Personett H, Gajic O, Kashyap R, Schramm G . Predictors of mortality among bacteremic patients with septic shock receiving appropriate antimicrobial therapy. BMC Anesthesiol. 2014; 14:21. PMC: 3987695. DOI: 10.1186/1471-2253-14-21. View

4.
Chawla L, Russell J, Bagshaw S, Shaw A, Goldstein S, Fink M . Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017; 19(1):43-49. View

5.
Khanna A, English S, Wang X, Ham K, Tumlin J, Szerlip H . Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017; 377(5):419-430. DOI: 10.1056/NEJMoa1704154. View